Prior to the event, RTP will work with a group of 5 community-based medical oncologists to collect challenging cases from their practices in addition to any relevant questions these individuals have related to the care of their patients. To begin each meeting module, Dr Love will present one or more of these cases and the related questions and ask the faculty to provide their perspectives. Afterward, the faculty will review available data sets and provide perspectives on their clinical implications as part of a moderated discussion.

MODULE 1: Hepatocellular Carcinoma (HCC) — Dr El-Khoueiry and Dr Finn

• Efficacy and safety outcomes from the Phase III REFLECT trial comparing lenvatinib to sorafenib as first-line therapy for unresectable HCC; recent FDA approval of lenvatinib and patient selection for its use in routine practice
• Available data with and sequence and selection of approved agents (nivolumab, regorafenib, cabozantinib, pembrolizumab) for patients whose disease has progressed on first-line therapy
• Key findings from the Phase III REACH-2 study of ramucirumab for patients with progressive HCC and elevated alpha-fetoprotein levels; future development plans
• Biologic rationale for and early trial data with atezolizumab/bevacizumab as first-line therapy for advanced HCC; FDA breakthrough therapy designation and ongoing Phase III evaluation
• Biologic rationale for, early safety and efficacy with and ongoing evaluation of combined anti-PD-1/PD-L1 and anti-CTLA-4 antibodies in HCC (eg, nivolumab/ipilimumab, durvalumab/tremelimumab)
• Active Phase III trials attempting to improve outcomes over standard biologic therapy for patients with newly diagnosed, advanced HCC (eg, CheckMate 459, LEAP-002, COSMIC-312)

MODULE 2: Pancreatic Adenocarcinoma (PAD) — Dr Bekaii-Saab and Dr O’Reilly

• Key outcomes from and clinical implications of the randomized Phase III Unicancer GI PRODIGE 24/CCTG PA.6 trial comparing adjuvant mFOLFIRINOX to gemcitabine for resected PAD
• Preliminary results from the Phase III APACT trial evaluating nanoparticle albumin-bound (nab) paclitaxel/gemcitabine versus gemcitabine alone in the adjuvant setting
• Use of contemporary chemotherapy regimens (mFOLFIRINOX, nab paclitaxel/gemcitabine) with or without radiation therapy as neoadjuvant treatment for resectable or borderline-resectable PAD
• Published research experience with, patient selection for and practical integration of nal-IRI (nanoliposomal irinotecan) in relapsed metastatic PAD
• Design, eligibility criteria and achievement of the primary progression-free survival endpoint in the Phase III POLO trial evaluating olaparib as maintenance therapy for patients with metastatic PAD with a germline BRCA mutation after first-line chemotherapy; diagnostic and clinical implications
• Mechanism of action, early activity and safety data and ongoing Phase III evaluation of other novel agents (eg, napabucasin, PEGPH20)

MODULE 3: Gastroesophageal Cancers — Dr Chao and Dr Janjigian

• Integration of ramucirumab into current clinical algorithms for metastatic gastric/gastroesophageal junction (GEJ) cancer
• Research supporting the FDA approval of pembrolizumab for recurrent or advanced gastric/GEJ adenocarcinoma with a PD-L1 combined positive score (CPS) ≥1 after 2 or more lines of chemotherapy and, if appropriate, HER2-targeted therapy; clinical and research implications of the Phase III KEYNOTE-061 and KEYNOTE-062 trials
• Early experience and ongoing research combining immune checkpoint inhibitors with chemotherapy, targeted therapy or other immunotherapeutic agents
• Primary and secondary endpoints achieved in the Phase III TAGS study of TAS-102 for heavily pretreated metastatic gastric cancer; FDA approval and patient selection in routine practice
• Results from the Phase III KEYNOTE-181 trial evaluating second-line pembrolizumab versus chemotherapy for locally advanced or metastatic squamous cell carcinoma and adenocarcinoma of the esophagus; potential role of pembrolizumab for progressive, PD-L1-positive advanced esophageal cancer

MODULE 4: Colorectal Cancer (CRC) — Prof Arnold and Dr Kopetz

• Available research data exploring the correlation between tumor location and long-term outcomes in metastatic CRC (mCRC); emerging data linking tumor sidedness to response to specific therapeutic interventions
• Rational incorporation of EGFR antibodies, regorafenib and TAS-102 into current treatment algorithms
• Published research information with the use of novel combination approaches for patients with advanced disease harboring a BRAF V600E tumor mutation (eg, irinotecan/vemurafenib/cetuximab, encorafenib/binimetinib/cetuximab); NCCN guideline inclusion and current clinical role, if any
• Research supporting the FDA approvals of pembrolizumab, nivolumab and nivolumab/ipilimumab for microsatellite instability (MSI)-high/mismatch repair-deficient mCRC
• Biologic rationale for, available research evidence with and ongoing evaluation of other immune checkpoint inhibitors alone or in combination with other systemic therapies for patients with MSI-high and microsatellite-stable mCRC